FB 825

Drug Profile

FB 825

Alternative Names: Anti-CEmX monoclonal antibody - Fountain Biopharma; FB-825; h4B12

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Academia Sinica
  • Developer Fountain BioPharma
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; IgE receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Job syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Allergic asthma; Allergic rhinitis

Most Recent Events

  • 26 Oct 2017 Phase-II clinical trials in Atopic dermatitis in USA (IV) before October 2017 (9227300; MicroBioGroup and Fountain Biopharma pipeline, October 2017)
  • 11 Oct 2017 FB 825 receives Orphan Drug status for Job syndrome (Hyperimmunoglobulin E syndrome) in USA
  • 01 Feb 2016 Fountain BioPharma completes a phase I trial in Atopic dermatitis, allergic asthma and allergic rhinitis (In volunteers) in USA (NCT02309762)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top